Pertuzumab
- Generic Name
- Pertuzumab
- Brand Names
- Perjeta, Perjeta-Herceptin, Phesgo
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 380610-27-5
- Unique Ingredient Identifier
- K16AIQ8CTM
- Background
Pertuzumab is a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (subdomain II) of the human epidermal growth factor receptor 2 protein (HER2). It consists of two heavy chains and two lights chains that have 448 and 214 residues respectively. It was first approved by the FDA in 2012 for use with docetaxel and anoth...
- Indication
Pertuzumab is indicated for intravenous administration in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. It is also indicated in combination with trastuzumab and other chemotherapies for the neoadjuvant t...
- Associated Conditions
- Inflammatory Breast Cancer (IBC), Locally Advanced Breast Cancer (LABC), Metastatic Breast Cancer, Stage I Breast Cancer
- Associated Therapies
- -
Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2013-05-06
- Last Posted Date
- 2021-09-10
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 10
- Registration Number
- NCT01847001
- Locations
- 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States
Trastuzumab & Pertuzumab Followed by T-DM1 in MBC
- Conditions
- Interventions
- First Posted Date
- 2013-04-18
- Last Posted Date
- 2021-03-30
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 208
- Registration Number
- NCT01835236
- Locations
- 🇨🇭
Hirslanden Klinik Aarau, Aarau, Switzerland
🇨🇭Kantonspital Aarau, Aarau, Switzerland
🇨🇭Kantonsspital Baden, Baden, Switzerland
A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Combination of Trastuzumab and Pertuzumab With or Without Concurrent Taxane Chemotherapy Given for Twelve Weeks in Patients With Operable HER2+/HR- Breast Cancer Within the ADAPT Protocol
- Conditions
- Interventions
- First Posted Date
- 2013-03-25
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- West German Study Group
- Target Recruit Count
- 220
- Registration Number
- NCT01817452
- Locations
- 🇩🇪
Ev. Krankenhaus Bethesda Brustzentrum Niederrhien, Moenchengladbach, Germany
Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa
- Conditions
- Interventions
- First Posted Date
- 2013-02-21
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 23
- Registration Number
- NCT01796197
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸University of Michigan, Ann Arbor, Michigan, United States
A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-01-24
- Last Posted Date
- 2020-12-30
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 780
- Registration Number
- NCT01774786
- Locations
- 🇺🇸
Florida Cancer Specialists - SCRI; Pharmacy, Fort Myers, Florida, United States
🇺🇸Weill Medical College of Cornell University; Division of Hematology & Medical Oncology, New York, New York, United States
🇺🇸University Of Chicago Medical Center; Section Of Hematology/Oncology, Chicago, Illinois, United States
Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE)
- Conditions
- Interventions
- First Posted Date
- 2012-09-13
- Last Posted Date
- 2017-05-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 208
- Registration Number
- NCT01684878
- Locations
- 🇳🇱
Academ Ziekenhuis Groningen; Medical Oncology, Groningen, Netherlands
🇳🇱Academisch Ziekenhuis Leiden; Clinical Oncology, Leiden, Netherlands
🇳🇱UMC St Radboud, Nijmegen, Netherlands
A Study of Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) in Participants With Metastatic Breast Cancer
- First Posted Date
- 2012-08-28
- Last Posted Date
- 2016-08-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 95
- Registration Number
- NCT01674062
A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-04-05
- Last Posted Date
- 2020-09-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1436
- Registration Number
- NCT01572038
- Locations
- 🇦🇷
Centro Oncologico Riojano Integral (CORI), La Rioja, Argentina
🇦🇹LKH-UNIV. KLINIKUM GRAZ; Klinische Abteilung für Onkologie, Graz, Austria
🇧🇪UZ Brussel, Brussel, Belgium
A Study to Assess Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in Participants With Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-03-28
- Last Posted Date
- 2016-11-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 213
- Registration Number
- NCT01565083
A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-12-14
- Last Posted Date
- 2020-10-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 258
- Registration Number
- NCT01491737
- Locations
- 🇹🇷
Ankara City Hospital, Ankara, Turkey
🇺🇸Washington University School of Medicine; Internal Medicine - Renal, Saint Louis, Missouri, United States
🇺🇸Ironwood Cancer TX & Rsch Ctrs, Chandler, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.